Pharma giant strikes deal to save breast cancer drug funding
By Nick Renaud-Komiya2015-03-17T12:46:00
The Swiss drug giant Novartis has struck a deal with NHS England to prevent one of its breast cancer treatments being axed from the cancer drugs fund.
You need to be signed in to read more
Subscribe for unlimited access
With a HSJ subscription you’ll unlock:
- All of HSJ.co.uk and our HSJ mobile app
- News and insight on all areas of public funded healthcare
- Expert commentary, insight and analysis from industry leaders
- 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics
HSJ is part of Wilmington Healthcare Limited. Company number 2530185. c/o Wilmington plc, 5th Floor, 10 Whitechapel High Street, London E1 8QS. Registered in England and Wales. Company registration 30158470
Site powered by Webvision Cloud